EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY 4.0

Diagnostic performances of Schistosoma haematobium and Schistosoma mansoni recombinant proteins, peptides and chimeric proteins antibody based tests. Systematic scoping review

Arthur Vengesai iD, Victor Muleya iD, Herald Midzi, Tryphine Vimbai Tinago, Isaac Chipako, Marble Manuwa, Thajasvarie Naicker, Takafira Mduluza

PLOS ONE · 02.03.2023 · 18 (3) · e0282233

DOI: 10.1371/journal.pone.0282233 ↗

Kurz gefasst

Scoping Review in der Zeitschrift PLOS ONE, online erschienen am 02.03.2023. Verfasst von Arthur Vengesai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Faculty of Medicine and Health Sciences, Midlands State University, Gweru, Zimbabwe. Hauptthemen laut MEDLINE: Schistosoma haematobium, Blood Group Antigens. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Traditional diagnostic tests for schistosome infections are suboptimal, particularly when the parasite burden is low. In the present review we sought to identify recombinant proteins, peptides, and chimeric proteins with potential to be used as sensitive and specific diagnostic tools for schistosomiasis.

Methods

The review was guided by PRISMA-ScR guidelines, Arksey and O’Malley’s framework, and guidelines from the Joanna Briggs Institute. Five databases were searched: Cochrane library, PubMed, EMBASE, PsycInfo and CINAHL, alongside preprints. Identified literature were assessed by two reviewers for inclusion. A narrative summary was used to interpret the tabulated results.

Results

Diagnostic performances were reported as specificities, sensitivities, and AUC. The AUC for S . haematobium recombinant antigens ranged from 0.65 to 0.98, and 0.69 to 0.96 for urine IgG ELISA. S . mansoni recombinant antigens had sensitivities ranging from 65.3% to 100% and specificities ranging from 57.4% to 100%. Except for 4 peptides which had poor diagnostic performances, most peptides had sensitivities ranging from 67.71% to 96.15% and specificities ranging from 69.23% to 100%. S . mansoni chimeric protein was reported to have a sensitivity of 86.8% and a specificity of 94.2%.

Conclusion

The tetraspanin CD63 antigen had the best diagnostic performance for S . haematobium . The tetraspanin CD63 antigen Serum IgG POC-ICTs had a sensitivity of 89% and a specificity of 100%. Peptide Smp_150390.1 (216–230) serum based IgG ELISA had the best diagnostic performance for S . mansoni with a sensitivity of 96.15% and a specificity of 100%. Peptides were reported to demonstrate good to excellent diagnostic performances. S . mansoni multi-peptide chimeric protein further improved the diagnostic accuracy of synthetic peptides. Together with the advantages associated with urine sampling technique, we recommend development of multi-peptide chimeric proteins urine based point of care tools.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Schistosoma haematobiumBlood Group AntigensAnimalsSchistosoma mansoniTetraspanin 30PeptidesRecombinant ProteinsRecombinant Fusion ProteinsImmunoglobulin G

Substanzen

Tetraspanin 30PeptidesBlood Group AntigensRecombinant ProteinsRecombinant Fusion ProteinsImmunoglobulin G

Autor:innen und Institutionen

  • Department of Biochemistry, Faculty of Medicine and Health Sciences, Midlands State University, Gweru, Zimbabwe.
  • Department of Biochemistry, University of Zimbabwe, Mt Pleasant, Harare, Zimbabwe.
  • Aravas Pharmaceuticals Pvt LTD, Prospect Industrial Area, Harare, Zimbabwe.
  • Discipline of Optics and Imaging, Doris Duke Medical Research Institute, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.

ORCID-Profile: Arthur Vengesai, Victor Muleya

Zitieren

APA

Vengesai, A., Muleya, V., Midzi, H., Tinago, T. V., Chipako, I., Manuwa, M., Naicker, T., & Mduluza, T. (2023). Diagnostic performances of Schistosoma haematobium and Schistosoma mansoni recombinant proteins, peptides and chimeric proteins antibody based tests. Systematic scoping review. PLOS ONE, 18(3), e0282233. https://doi.org/10.1371/journal.pone.0282233

Vancouver

Vengesai A, Muleya V, Midzi H, Tinago TV, Chipako I, Manuwa M, et al. Diagnostic performances of Schistosoma haematobium and Schistosoma mansoni recombinant proteins, peptides and chimeric proteins antibody based tests. Systematic scoping review. PLOS ONE. 2023;18(3):e0282233. doi:10.1371/journal.pone.0282233

BibTeX
@article{Vengesai2023,
  author = {Vengesai, Arthur and Muleya, Victor and Midzi, Herald and Tinago, Tryphine Vimbai and Chipako, Isaac and Manuwa, Marble and Naicker, Thajasvarie and Mduluza, Takafira},
  title = {Diagnostic performances of Schistosoma haematobium and Schistosoma mansoni recombinant proteins, peptides and chimeric proteins antibody based tests. Systematic scoping review},
  journal = {PLOS ONE},
  year = {2023},
  volume = {18},
  number = {3},
  pages = {e0282233},
  doi = {10.1371/journal.pone.0282233}
}
Kostenlos starten →